This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second View: Delving into the Phase III SUMMIT clinical trial of tirzepatide in patients with heart failure
Ticker(s): LLYWho's the expert?
Institution: North Shore Heart and Vascular
-
Board certified in Interventional Cardiology while also specializing in nuclear cardiology
-
manages treatment for 50 patients with Hypertrophic Cardiomyopathy
-
very familiar with Mavacamten, VALOR-HCM, and EXPLORER-LTE clinical trial
Interview Goalto discuss the current standard of care and the potential of tirzepatide, a GLP-1 and GIP receptor agonist for reducing the risk of heart failure.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
